Attached files
| file | filename |
|---|---|
| 10-K - 10-K - ALPINE IMMUNE SCIENCES, INC. | alpn-20201231.htm |
| EX-32.2 - EX-32.2 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex322_20201231.htm |
| EX-32.1 - EX-32.1 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex321_20201231.htm |
| EX-31.2 - EX-31.2 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex312_20201231.htm |
| EX-31.1 - EX-31.1 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex311_20201231.htm |
| EX-10.6 - EX-10.6 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex106_20201231.htm |
| EX-4.10 - EX-4.10 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex410_20201231.htm |
| EX-3.2 - EX-3.2 - ALPINE IMMUNE SCIENCES, INC. | alpn-ex32_20201231.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-8 No. 333-205220) pertaining to the 2012 Stock Incentive Plan of N30 Pharmaceuticals, Inc., 2015 Equity Incentive Plan of Nivalis Therapeutics, Inc. and Employee Stock Purchase Plan of Nivalis Therapeutics, Inc., | ||||||||||
| (2) | Registration Statement (Form S-8 No. 333-211197) pertaining to the Employment Inducement Awards of Nivalis Therapeutics, Inc., | ||||||||||
| (3) | Registration Statement (Post-Effective Amendment No. 1 on Form S-8 to Form S-4 No. 333-218134) pertaining to the Amended and Restated 2015 Stock Plan of Alpine Immune Sciences, Inc., | ||||||||||
| (4) | Registration Statement (Form S-8 No. 333-223965) pertaining to the Amended and Restated 2015 Stock Plan, as amended, and the 2015 Equity Incentive Plan of Alpine Immune Sciences, Inc., | ||||||||||
| (5) | Registration Statement (Form S-8 No. 333-225792, No. 333-230369, No. 333-237479, and No. 333-239233) pertaining to the 2018 Equity Incentive Plan of Alpine Immune Sciences, Inc., | ||||||||||
| (6) | Registration Statement (Form S-1 No. 333-230365) and related Prospectus of Alpine Immune Sciences, Inc. for the registration of 6,542,310 shares of its common stock, | ||||||||||
| (7) | Registration Statement (Form S-1 No. 333-244409) and related Prospectus of Alpine Immune Sciences, Inc. for the registration 7,709,416 shares of its common stock, | ||||||||||
| (8) | Registration Statement (Form S-8 No. 333-230372) pertaining to the Stand-Alone Inducement Stock Option Grant of Alpine Immune Sciences, Inc., and | ||||||||||
| (9) | Registration Statement (Form S-3 No. 333-239760) of Alpine Immune Sciences, Inc. to offer or sell securities for the aggregate offering price of up to $60,000,000 | ||||||||||
of our report dated March 18, 2021, with respect to the consolidated financial statements of Alpine Immune Sciences, Inc., included in this Annual Report (Form 10-K) of Alpine Immune Sciences, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young
Seattle, Washington
March 18, 2021